In recent months, the life sciences industry has seen the reemergence of contingent value rights, or CVRs, in public company acquisitions as a way to bridge a valuation gap between buyers and sellers. Recent public deals with CVRs include AstraZeneca’s acquisition of CinCor Pharma completed…
Source: corpgov.law.harvard.edu – Read more
Threat Actors Attacking Job Seekers With Three New Unique Adversaries
A surge in sophisticated recruitment scams targets job seekers, exploiting economic vulnerabilities. Cybercriminals use social engineering to blend legitimate practices with fraud, resulting in over
